Important announcements in Hong Kong stocks today:
1) Company News
$YUEXIU PROPERTY (00123.HK)$The consortium won the bid for the Yangsi land parcel in Pudong, shanghai for 7.897 billion yuan through public auction.
$BOSIDENG (03998.HK)$The interim results were announced, with profits attributable to shareholders rising 23% year-on-year to approximately 1.13 billion yuan, and a dividend of 6 Hong Kong cents per share.
$CHINA QINFA (00866.HK)$The subsidiary completed the sale of 40% equity in Liyuan Development for a consideration of 2.95 billion yuan.
$WASION HOLDINGS (03393.HK)$: The subsidiary Wasion Holdings secured a contract for approximately 0.662 million smart meters, valued at about 0.175 billion yuan.
$PACIFIC BASIN (02343.HK)$: Plans to acquire two new dual-fuel methanol ultra-large handy bulk carriers for 93 million US dollars.
$CHALCO (02600.HK)$: Three subsidiaries plan to acquire a series of flat rolling assets, with a total price of 0.175 billion yuan.
$GRAND PHARMA (00512.HK)$: The global innovative radiolabeled drug TLX250-CDx has completed the first patient enrollment in a Phase III clinical study in China.
$HISENSE HA (00921.HK)$From July 1, 2024, to November 28, 2024, the subsidiary air conditioner marketing company, Guoloni Company, Hisense Ha Molding Company, Kelon Molding Company, refrigerator marketing company, and Rongsong Plastic Company subscribed to insurance financial products totaling 1.895 billion yuan.
2) Progress of pharmaceutical company's negotiations with national medical insurance.
$HANSOH PHARMA (03692.HK)$ Four innovative drugs will be renewed and included in the 2024 national medical insurance catalog.
$SIMCERE PHARMA (02096.HK)$Kexai La, Enlituz, and Xianbixin three innovative drugs have been included in the new national medical insurance drug list.
$ASCENTAGE-B (06855.HK)$: Naikek's new indication has been included in the latest National Medical Insurance Drug List. This drug is an original Class 1 new drug that has received national support for "significant new drug creation" and is primarily used for patients with chronic myeloid leukemia.
$ANTENGENE-B (06996.HK)$: Xivio's indication for the treatment of diffuse large B-cell lymphoma has successfully been included in the 2024 edition of the National Medical Insurance Drug List.
$JUNSHI BIO (01877.HK)$: Tuoyi's new indication has been included in the National Medical Insurance Directory, making it the only anti-PD-1 monoclonal antibody in the National Medical Insurance Directory used for the treatment of melanoma, non-small cell lung cancer during the perioperative period, renal cancer, and triple-negative breast cancer.
$HUTCHMED (00013.HK)$: Vorozole has successfully renewed its contract with the China National Medical Insurance Drug List under current terms for the treatment of non-small cell lung cancer patients with specific MET exon 14 skipping mutations.
$INNOVENT BIO (01801.HK)$The new drug Xinbile (Torecizumab injection) and the new indication of Nailik (Orelabrutinib) have been included in the 2024 edition of the National Medical Insurance Drug List.
3) Financing, shareholding, and buyback dynamics.
$IMMUNEONCO-B (01541.HK)$Completed the placement of a total of 33.15 million shares, raising approximately 0.23 billion Hong Kong dollars.
$YANKUANG ENERGY (01171.HK)$The controlling shareholder Yankuang Energy has cumulatively increased its holdings by 27.71538 million shares, and the shareholding plan has been fully implemented.
$TENCENT (00700.HK)$Invested approximately 0.7 billion Hong Kong dollars to repurchase 1.75 million shares, with a buyback price of 397.6-403.8 Hong Kong dollars.
$AIA (01299.HK)$Invested 0.452 billion Hong Kong dollars to repurchase 7.807 million shares, with a buyback price of 56.8-58.35 Hong Kong dollars.
$HSBC HOLDINGS (00005.HK)$Invested 0.127 billion Hong Kong dollars to repurchase 1.7788 million shares, with a buyback price of 71.5-72.1 Hong Kong dollars.
$SINOPEC CORP (00386.HK)$Invested approximately 28.1748 million Hong Kong dollars to repurchase 6.764 million shares, with a buyback price of 4.15-4.2 Hong Kong dollars.
$COSCO SHIP HOLD (01919.HK)$Spent 26.3274 million HKD to repurchase 2.42 million shares at a repurchase price of 10.82-11.06 HKD.
Editor/new
